References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424. doi: 10.3322/caac.21492
- Ren Y, Qiu H, Yuan Y, Ye J, Tian Y, Wen B, et al. Evaluation of 7th edition of AJCC staging system for nasopharyngeal carcinoma. J Cancer 2017; 8: 166572. doi: 10.7150/jca.19197
- Zhang MX, Li J, Shen GP, Zou X, Xu JJ, Jiang R, et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up. Eur J Cancer 2015; 51: 2587-95. doi: 10.1016/j.ejca.2015.08.006
- Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet 2016; 388: 1883-92. doi: 10.1016/S0140-6736(16)31388-5
- Yang Y, Qu S, Li J, Hu C, Xu M, Li W, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2021; 22: 1162-74. doi: 10.1016/S1470-2045(21)00302-8
- Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med 2021; 27: 153643. doi: 10.1038/s41591-021-01444-0
- Yang Y, Pan J, Wang H, Zhao Y, Qu S, Chen N, et al. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309). Cancer Cell 2023; 41: 1061-72.e4. doi: 10.1016/j.ccell.2023.04.014
- Wong KCW, Hui EP, Lo KW, Lam WKJ, Johnson D, Li L, et al. Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol 2021; 18: 679-95. doi: 10.1038/s41571-021-00524-x
- Lv JW, Li JY, Luo LN, Wang ZX, Chen YP. Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials. J Immunother Cancer 2019; 7: 159. doi: 10.1186/s40425-019-0636-7
- Chong WQ, Low JL, Tay JK, Le TBU, Goh GS, Sooi K, et al. Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial. Lancet Oncol 2025; 26: 175-86. doi: 10.1016/S1470-2045(24)00677-6
- Chan ATC, Lee VHF, Hong RL, Ahn MJ, Chong WQ, Kim SB, et al. Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial. Ann Oncol 2023; 34: 251-61. doi: 10.1016/j.annonc.2022.12.007
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74. doi: 10.1016/j.cell.2011.02.013
- Lee V, Kwong D, Leung TW, Lam KO, Tong CC, Lee A. Palliative systemic therapy for recurrent or metastatic nasopharyngeal carcinoma - How far have we achieved? Crit Rev Oncol Hematol 2017; 114: 13-23. doi: 10.1016/j. critrevonc.2017.03.030
- Qin S, Li A, Yi M, Yu S, Zhang M, Wu K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol 2019; 12: 27. doi: 10.1186/s13045-019-0718-5
- Lee NY, Zhang Q, Pfister DG, Kim J, Garden AS, Mechalakos J, et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol 2012; 13: 172-80. doi: 10.1016/S1470-2045(11)70303-5
- Hui EP, Ma BBY, Loong HHF, Mo F, Li L, King AD, et al. Efficacy, safety, and pharmacokinetics of axitinib in nasopharyngeal carcinoma: a preclinical and phase II correlative study. Clin Cancer Res 2018; 24: 1030-7. doi: 10.1158/1078-0432.CCR-17-1667
- Ruan X, Liang JH, Pan Y, Cai R, Zhang RJ, He Z, et al. Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: a multicenter, single-arm, prospective phase 2 study. Cancer 2021; 127: 3163-71. doi: 10.1002/cncr.33626
- Sun Y, Niu W, Du F, Du C, Li S, Wang J, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol 2016; 9: 105. doi: 10.1186/s13045-016-0332-8
- Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol 2018; 4: 1569-75. doi: 10.1001/jamaoncol.2018.3039
- Cui Q, Hu Y, Ma D, Liu H. A retrospective observational study of anlotinib in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Drug Des Devel Ther 2021; 15: 339-47. doi: 10.2147/DDDT.S286529
- Hui EP, Ma BBY, King AD, Mo F, Chan SL, Kam MKM, et al. Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. Ann Oncol 2011; 22: 1280-7. doi: 10.1093/annonc/mdq629
- Lim WT, Ng QS, Ivy P, Leong SS, Singh O, Chowbay B, et al. A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma. Clin Cancer Res 2011; 17: 5481-9. doi: 10.1158/1078-0432.CCR-10-3409
- Elser C, Siu LL, Winquist E, Agulnik M, Pond GR, Chin SF, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007; 25: 3766-73. doi: 10.1200/JCO.2006.10.2871
- Huang L, Zhang X, Bai Y, Chua KLM, Xie Y, Shu X, et al. Efficacy and safety of apatinib in recurrent/metastatic nasopharyngeal carcinoma: a pilot study. Oral Oncol 2021; 115: 105222. doi: 10.1016/j.oraloncology.2021.105222
- Fang Y, Su N, Zou Q, Cao Y, Xia Y, Tang L, et al. Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial. BMC Med 2023; 21: 423. doi: 10.1186/s12916-023-03140-x
- Lin B, Song X, Yang D, Bai D, Yao Y, Lu N. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. Gene 2018; 654: 77-86. doi: 10.1016/j.gene.2018.02.026
- Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, et al. Anlotinib: a novel multitargeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol 2018; 11: 120. doi: 10.1186/s13045-018-0664-7
- Gao Y, Liu P, Shi R. Anlotinib as a molecular targeted therapy for tumors. Oncol Lett 2020; 20: 1001-14. doi: 10.3892/ol.2020.11685